PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
An open-label, single-arm, post- authorization pragmatic clinical trial on the safety and
efficacy of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in subjects with hemophilia A
in usual care settings in China for approximately 6 months or or approximately 50 exposure
days whichever occurs first